Finasteride has long been linked to high-grade prostate cancer, hindering its use as a chemoprevention agent. Long-term data, however, suggest no such risk exists.
Researchers say they can distinguish between lesions that are benign and those that could become invasive — but the technology required is not yet used routinely.
Despite newer agents being available to patients with multiple myeloma, the rate of infections in this patient population has remained relatively unchanged.
